Raynaud phenomenon in dermatology. Part 2: Therapy;Raynaud-phänomen in der dermatologie. Teil 2: Therapie

Hautarzt

Volumn 57, Issue 10, 2006, Pages 927-942

  Sunderkotter C ^b   Riemekasten, G ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Endothelin; Iloprost; Raynaud; Scleroderma; Sildenafil; Vascular damage

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMLODIPINE; ANTIOXIDANT; ARTHROTEC; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPYRIDAMOLE; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; FLUOXETINE; GINKGO BILOBA EXTRACT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; ISRADIPINE; LOSARTAN; NIFEDIPINE; NITRATE; PENTOXIFYLLINE; PRAZOSIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1; PROSTAVASIN; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; UNINDEXED DRUG;

AMPUTATION; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HUMAN; HYPERTENSION; META ANALYSIS; RAYNAUD PHENOMENON; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; ULCER; VASODILATATION;

HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 33749526134     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1218-4     Document Type: Review

References (33)

1. Bali G, Aberer E (2003) Iloprost therapy in systemic sclerosis. Hautarzt 54: 845-851
2. Beckett VL, Conn DL, Fuster V et al. (1984) Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 27: 1137-1143
3. Bettoni L, Geri A, Airo P et al. (2002) Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21: 244-250
4. Ceru S, Pancera P, Sansone S et al. (1997) Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis. Clin Exp Rheumatol 15: 381-385
5. Challenor VF, Waller DG, Hayward RA et al. (1991) Subjective and objective assessment of enalapril in primary Raynaud's phenomenon. Br J Clin Pharmacol 31: 477-480
6. Coleiro B, Marshall SE, Denton CP et al. (2001) Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40: 1038-1043
7. Cracowski JL, Girolet S, Imbert B et al. (2005) Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radic Biol Med 38: 98-103
8. Denton CP, Howell K, Stratton RJ, Black CM (2000) Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 18: 499-502
9. Dziadzio M, Denton CP, Smith R et al. (1999) Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42: 2646-2655
10. Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112: 2980-2985
11. Goldberg J, Dlesk A (1986) Successful treatment of Raynaud's phenomenon with pentoxifylline. Arthritis Rheum 29: 1055-1056
12. Hummers LK, Wigley FM (2003) Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29: 293-313
13. Kahan A, Amor B, Menkes CJ (1985) A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 44: 30-33
14. Meyrick Thomas RH, Rademaker M, Grimes SM et al. (1987) Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Br J Dermatol 117: 237-241
15. Mohrland JS, Porter JM, Smith EA et al. (1985) A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome. Ann Rheum Dis 44: 754-760
16. Muir AH, Robb R, McLaren M et al. (2002) The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vasc Med 7: 265-267
17. Namazi MR (2004) Statins: novel additions to the dermatologic arsenal? Exp Dermatol 13: 337-339
18. Pope J, Fenlon D, Thompson A et al. (2000) Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev: CD000953
19. Pope J, Fenlon D, Thompson A et al. (2000) Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev: CD000954
20. Pope J, Fenlon D, Thompson A et al. (2000) Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev: CD000956
21. Rademaker M, Cooke ED, Almond NE et al. (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. Bmj 298: 561-564
22. Rhedda A, McCans J, Willan AR, Ford PM (1985) A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. J Rheumatol 12: 724-727
23. Riemekasten G, Sunderkotter C (2006) Vasoactive therapies in systemic sclerosis. Rheumatology (Oxford) (in press)
24. Riemekasten G, Jepsen H, Burmester GR, Hiepe F (1998) Iloprost administration over 21 days as an effective therapy in systemic scleroderma-case report and review of the literature. Z Rheumatol 57: 118-124
25. Rustin MH, Almond NE, Beacham JA et al. (1987) The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol 117: 751-758
26. Schmidt JF, Valentin N, Nielsen SL (1989) The clinical effect of felodipine and nifedipine in Raynaud's phenomenon. Eur J Clin Pharmacol 37: 191-192
27. Scorza R, Caronni M, Mascagni B et al. (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19: 503-508
28. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113: 352-357
29. Stratton R, Shiwen X, Martini G et al. (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108: 241-250
30. Sunderkotter C, Riemekasten G (2006) Das Raynaud Phänomen in der Dermatologie Teil 1: Pathophysiologie und Diagnostik. Hautarzt (in press)
31. Teh LS, Manning J, Moore T et al. (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 34: 636-641
32. Thompson AE, Shea B, Welch V et al. (2001) Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 44: 1841-1847
33. Yung A, Reay N, Goodfield MD (2005) Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (viagra) in limited systemic sclerosis. Arch Dermatol 141: 831-833